ANL

Rating neutralAI Memo

Adlai Nortye Group

As of 2026-04-15/Confidence low/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

low

Horizon

6‑12m

Key catalyst

AN9025 clinical execution becomes the lead proof point • 2026-09-30

Base target: $11 / p=45% prob

Biggest risk

The bearish case is that the only late-stage asset already failed and was discontinued [#PR-2025-05-30], so the story has reset to early-stage, high-burn oncology programs with limited human efficacy evidence. Even after the PIPE, execution risk, dilution history, and the absence of confirmed follow-through on older milestones keep ANL in a low-conviction monitoring bucket.

Invalidation

Break below $7 or thesis failure.

What would change my mind?

The bullish case is that the market is valuing ANL mainly as a damaged post-BURAN shell even though the company has now funded itself with a $140.0 million PIPE [#PR-2026-02-03], started AN9025 Phase 1 [#PR-2026-02-12], and still guides AN4035 toward mid-2026 IND [#6K-2025-12-29]. If AN9025 shows credible early clinical signals, the current market cap could look too low for a funded multi-asset oncology platform.

Research note

Recommendation

neutral

Confidence

low

As of

2026-04-15

Base target

$11

p=45%

Bull target

$16

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-BURAN balance-sheet reset is largely in place
AN4035 IND timing is a secondary pipeline option
The bullish case is that the market is valuing ANL mainly as a damaged post-BURAN shell even though the company has now funded itself with a $140.0 million PIPE [#PR-2026-02-03], started AN9025 Phase 1 [#PR-2026-02-12], and still guides AN4035 toward mid-2026 IND [#6K-2025-12-29].

BearKey bullets

AN4035 IND timing could slip beyond mid-2026, weakening the backup pipeline narrative.
AN9025 may fail to generate acceptable safety, PK, or early efficacy in Phase 1.
Low coverage and thin primary-source follow-through on expected milestones keep visibility weak.

WatchKey bullets

AN9025 clinical execution becomes the lead proof point

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $11 (p=45%)

Target spread vs base: +45% / -41%

Scenario probabilities

Bull Target: $16 (p=25%)Base Target: $11 (p=45%)Bear Target: $7 (p=30%)

Commentary

Sentiment is cautious-neutral. Primary-source confirmation improved the setup versus the raw packet: the company absorbed a major negative in the May 30, 2025 BURAN failure and discontinuation [#PR-2025-05-30], then recapitalized with a $140.0 million PIPE on February 3, 2026 [#PR-2026-02-03] and advanced AN9025 into Phase 1 with first-patient dosing on February 12, 2026 [#PR-2026-02-12]. That said, forward visibility is still weak because the remaining thesis depends on very early-stage assets, and some previously guided milestones from older disclosures are not yet clearly resolved in the sources checked. This remains more of a funded monitoring story than a high-conviction bullish setup.

As of 2026-04-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-BURAN balance-sheet reset is largely in place
AN4035 IND timing is a secondary pipeline option

Scenarios

Bull Target (Scenario probability)

$16 / p=25% prob

Base Target (Scenario probability)

$11 / p=45% prob

Bear Target (Scenario probability)

$7 / p=30% prob

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-09-30
AN9025 clinical execution becomes the lead proof point
Adlai announced first-patient dosing in the U.S. Phase 1 AN9025 study on February 12, 2026 [#PR-2026-02-12]. With AN2025 discontinued, incremental enrollment, safety, or early pharmacology updates on AN9025 are now the main stock-specific upside driver.
Prob 55.00% • Move 22.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Post-BURAN balance-sheet reset is largely in place
2026-05-31
After discontinuing buparlisib following the failed Phase 3 BURAN readout [#PR-2025-05-30], Adlai raised approximately $140.0 million in a February 3, 2026 private placement, materially reducing immediate financing stress and allowing focus on RAS and immunotherapy assets [#PR-2026-02-03]. Near-term upside from this reset looks partly absorbed, but it lowers binary insolvency risk.
Prob 80% • Move 8% • Priced-in 75%

Long-term Catalysts

Months to a year

AN4035 IND timing is a secondary pipeline option
2026-07-15
The December 29, 2025 6-K said Adlai expects to submit an IND for AN4035 in the middle of 2026 [#6K-2025-12-29]. Hitting that timing would support the view that the post-BURAN company still has more than one forward program, though the value impact should stay below AN9025 until human data arrive.
Prob 45% • Move 15% • Priced-in 25%

Risks

AN4035 IND timing could slip beyond mid-2026, weakening the backup pipeline narrative.
AN9025 may fail to generate acceptable safety, PK, or early efficacy in Phase 1.
Low coverage and thin primary-source follow-through on expected milestones keep visibility weak.
Small-cap biotech volatility can cause large moves unrelated to fundamentals.
The company remains dependent on external financing and partner execution despite the February 2026 PIPE.

Peers

Symbol	Summary
ALGS	Aligos is a loose small-cap biotech comp by size rather than mechanism; like ANL, valuation can swing sharply on clinical progress versus financing pressure.
JSPR	Jasper is another loose clinical-stage small-cap peer where single-program execution and capital access dominate trading, reinforcing ANL's event-driven risk profile.
PASG	Passage Bio is not a direct operating peer, but it is useful as another small-cap development-stage biotech showing how pipeline setbacks and financing needs can overwhelm platform optionality.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-15

Loading AI feed…

Symbol

Summary

ALGS

Aligos is a loose small-cap biotech comp by size rather than mechanism; like ANL, valuation can swing sharply on clinical progress versus financing pressure.

JSPR

Jasper is another loose clinical-stage small-cap peer where single-program execution and capital access dominate trading, reinforcing ANL's event-driven risk profile.

PASG

Passage Bio is not a direct operating peer, but it is useful as another small-cap development-stage biotech showing how pipeline setbacks and financing needs can overwhelm platform optionality.